EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

doi:10.1158/0008-5472.CAN-16-2224

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.

Cancer research - 15 Aug 2017

Etemadmoghadam Dariush, Azar Walid J, Lei Ying, Moujaber Tania, Garsed Dale W, Kennedy Catherine J, Fereday Sian, Mitchell Chris, Chiew Yoke-Eng, Hendley Joy, Sharma Raghwa, Harnett Paul R, Li Jason, Christie Elizabeth L, Patch Ann-Marie, George Joshy, Au-Yeung George, Mir Arnau Gisela, Holloway Timothy P, Semple Timothy, Pearson John V, Waddell Nicola, Grimmond Sean M, Köbel Martin, Rizos Helen, Lomakin Ivan B, Bowtell David D L, deFazio Anna

Abstract excerpt

Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF, and NRAS RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Gene Knockdown Techniques

Share to GTP Phosphohydrolases

Share to Mutagenesis, Site-Directed

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Source

Open in PubMed

Identifiers

PMID: 28646021
DOI: 10.1158/0008-5472.CAN-16-2224

Genes

NRAS
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.PMID 28646021Read ↗

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Semantic proximity Read ↗

Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.Semantic proximity Read ↗

Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.Semantic proximity Read ↗

Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.Semantic proximity Read ↗

Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapySemantic proximity Read ↗

Integrative Genomic and Functional Analysis Reveals NF1 Loss as a Modifier of DNA Damage and Replication Stress Responses in Ovarian Cancer.Semantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Semantic proximity Read ↗

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.Semantic proximity Read ↗

LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinomaSemantic proximity Read ↗

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Semantic proximity Read ↗

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.